Cost effectiveness of palivizumab in Spain: an analysis using observational data

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

PEDIATRICS · 1998 · 1.9K citations

Respiratory Virus Immunity, Viral Diagnostics, Respiratory Complications +17

Respiratory Syncytial Virus Bronchiolitis in Infancy Is an Important Risk Factor for Asthma and Allergy at Age 7

Nele Sigurs, Ragnar Bjarnason, F. Sigurbergsson et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 1.1K citations

Asthma, Environmental Allergy, Important Risk Factor +19

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Timothy F. Feltes, Allison K. Cabalka, H. Cody Meissner et al. · The Journal of Pediatrics · 2003 · 816 citations

Pediatric Heart Disease, Respiratory Diseases, Pediatrics +9

Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

Jessie R. Groothuis, Eric A. F. Simões, Myron J. Levin et al. · New England Journal of Medicine · 1993 · 744 citations · Full text

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

PubMed · 1998 · 638 citations

Respiratory Virus Immunity, Respiratory Complications, Immunology +17